Similar articles

• Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.

  Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ. Goswami NJ, et al. Catheter Cardiovasc Interv. 2010 Jan 1;75(1):93-100. doi: 10.1002/ccd.22194. Catheter Cardiovasc Interv. 2010. PMID: 19787803
• DES in SVGs: safe and at least short-term effective.

  Hillegass WB. Hillegass WB. Catheter Cardiovasc Interv. 2011 Feb 15;77(3):356-7. doi: 10.1002/ccd.22972. Catheter Cardiovasc Interv. 2011. PMID: 21328680 No abstract available.
• Revitalizing embolic protection in saphenous vein grafts.

  Satler LF. Satler LF. Catheter Cardiovasc Interv. 2010 Aug 1;76(2):270-1. doi: 10.1002/ccd.22708. Catheter Cardiovasc Interv. 2010. PMID: 20665876 No abstract available.
• The use of drug-eluting stents in venous coronary artery bypass grafts.

  Hernandez-Antolín R, Alfonso F, Jimenez P. Hernandez-Antolín R, et al. EuroIntervention. 2009 May;5 Suppl D:D51-7. EuroIntervention. 2009. PMID: 19736072 Review.
• Approach to the patient with prior bypass surgery.

  Nguyen T, Pham L, Cheem TH, Douglas JS, Hermiller J, Grines C. Nguyen T, et al. J Interv Cardiol. 2004 Oct;17(5):339-46. doi: 10.1111/j.1540-8183.2004.04033.x. J Interv Cardiol. 2004. PMID: 15491339 Review. No abstract available.